TORONTO--(BUSINESS WIRE)--SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, announced today it has raised gross proceeds of CDN $754,000 from the closing of the third and final tranche of a non-brokered private placement (the “Private Placement”) of 430,713 units (“Units”) priced at $1.75 per Unit. The aggregate gross proceeds raised by the Company in connection with the first, second and third tranches of the Private Placement is $5.659 million through the issuance of a total of 3,233,571 units.
